Welcome to our dedicated page for BIOC news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on BIOC stock.
Biocept, Inc. (BIOC) pioneers molecular diagnostics for cancer management through its proprietary Target Selector™ technology. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s advancements in liquid biopsy solutions and oncology research.
Access real-time announcements including financial results, strategic partnerships, and clinical validation studies. Our curated collection ensures efficient tracking of Biocept’s progress in developing non-invasive diagnostic tools that inform treatment decisions and improve patient care pathways.
Key updates cover regulatory milestones, technology enhancements, and collaborations with biopharmaceutical partners. Bookmark this page for direct access to primary source materials, including earnings calls analysis and product launch details, all organized for informed decision-making.
Biocept, Inc. (Nasdaq: BIOC) announced significant milestones as of December 14, 2020. The company has processed over 150,000 COVID-19 RT-PCR test samples, reporting most results within 48 hours. Additionally, Biocept successfully transitioned to a new corporate headquarters and molecular laboratory in San Diego, designed for operational efficiency and expected to reduce facility costs by 20% annually. All operations in the new facility are fully functional, enabling continued service in oncology and COVID-19 testing.
Biocept, Inc. (Nasdaq: BIOC) announced promising results from a study indicating the effectiveness of its Target Selector™ liquid biopsy in monitoring HER2 alterations in metastatic breast cancer patients. Conducted at Johns Hopkins, the study showed Target Selector™ to be highly accurate and less invasive than traditional tissue biopsies. Dr. Vered Stearns highlighted the importance of this method for tracking treatment response and identifying potential therapy adjustments. The findings were presented at the 2020 San Antonio Breast Cancer Symposium, emphasizing Biocept's commitment to enhancing patient outcomes through advanced diagnostics.
EIR Healthcare has launched MedModLabs, a modular healthcare initiative aimed at enhancing COVID-19 testing access through mobile, prefabricated sampling facilities. Developed in collaboration with Biocept (Nasdaq: BIOC), MedModLabs offers non-invasive oral swab tests with results in 1-2 business days and no prescription required. Despite a national average of 1.7 million daily tests, demand exceeds supply, particularly during holiday surges. MedModLabs is committed to providing 10% of its tests to underserved communities, and is currently operational in the greater Philadelphia area.
Biocept, Inc. (Nasdaq: BIOC) announces positive results from a study evaluating its Target Selector™ CSF assays for detecting circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) of patients with metastasized lung or breast cancer. The study, presented at the SNO2020 Virtual Conference, highlights the assays' sensitivity compared to traditional CSF cytology, which has limited accuracy. This minimally invasive technology could enhance patient monitoring and therapy selection while avoiding surgical risks. Biocept continues to progress in neuro-oncology, with this being the second significant conference to showcase their findings.
Biocept, Inc. (Nasdaq: BIOC) announced that results from a study using its Target Selector™ testing will be presented at the 2020 San Antonio Breast Cancer Symposium on December 9, 2020. The study evaluates liquid biopsies for monitoring HER2 status in metastatic breast cancer, addressing the challenges of obtaining tissue samples. Dr. Vered Stearns of Johns Hopkins will present findings that could inform treatment options for HER2-positive patients as their tumors progress.
Biocept, Inc. (Nasdaq: BIOC) reported a significant increase in third-quarter revenues for 2020, reaching $6.6 million, up from $1.5 million in Q3 2019, thanks to COVID-19 RT-PCR testing. The company processed over 52,993 samples during the quarter. Despite a net loss of $4.9 million, improvements in oncology testing volumes were noted, particularly in neuro-oncology. Biocept has also expanded its patent portfolio and received positive coverage for its Target Selector™ liquid biopsy assays, indicating strong future potential in oncology diagnostics.
Biocept, Inc. (Nasdaq: BIOC) announced it has processed over 100,000 COVID-19 samples through its RT-PCR technology at its CLIA-certified lab. The company provides testing for various clients, primarily in California, and aims to return results within 48 hours. CEO Michael Nall stated that the COVID-19 testing is expected to have a significant positive impact on revenues for 2020 and into 2021. Biocept also specializes in molecular diagnostics for different cancers, utilizing their proprietary liquid biopsy technology for patient monitoring and treatment.
Biocept, Inc. (NASDAQ: BIOC) announced its receipt of Hong Kong Patent No. 1188285 for methods and reagents that enhance the detection of circulating tumor cells (CTCs). This patent complements Biocept's existing technologies, which include antibody-based CTC enrichment and a patented blood transport tube for analysis. President and CEO Michael Nall highlighted that this patent supports the company's strategy for global growth, increasing its intellectual property portfolio to 44 patents focused on molecular diagnostics.
Biocept, Inc. (Nasdaq: BIOC) announced the award of Japanese Patent No. 6771010 for its devices and methods used to capture and analyze circulating tumor cells (CTCs) from biological samples. This patent enhances Biocept's intellectual property portfolio and enables the detection of various tumor types through binding entities such as antibodies. The technology supports existing platforms like their blood collection tube and Target Selector™ circulating DNA analysis, potentially leading to licensing opportunities with other companies.
Biocept, Inc. (Nasdaq: BIOC) will announce its financial results for Q3 2020 on November 12, 2020, after market close. The company will host a conference call at 4:30 PM ET to discuss the results and take questions from investors. Biocept specializes in molecular diagnostic tests for cancer, leveraging its proprietary Target Selector™ liquid biopsy technology to provide actionable insights for treatment and monitoring. The firm also supports COVID-19 testing initiatives. Investors can pre-register for the call to streamline access.
